The effectiveness of cyclic and continuous oral clodronate therapy on bone density and markers in osteopenic postmenopausal women

Calcified Tissue International

Volumn 64, Issue 5, 1999, Pages 384-388

  Tsai, K S ^a   Hsu, S H J ^a   Yang, R S ^a   Cheng, W C ^a   Chieng, P U ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Bone resorption markers; Clodronate; Continuous; Cyclic; Postmenopausal osteopenia

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID;

ADULT; AGED; ARTICLE; BONE ATROPHY; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS LINKING; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; VERTEBRA FRACTURE;

ADMINISTRATION, ORAL; AGED; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; CLODRONIC ACID; COLLAGEN; COLLAGEN TYPE I; CROSS-OVER STUDIES; DENSITOMETRY, X-RAY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEMUR NECK; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; TREATMENT OUTCOME;

EID: 0032921550     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00005819     Document Type: Article

References (24)

1. Fleisch H, Russell RGG, Francis MD (1969) Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165:1261-1264
2. Fleisch H (1991) Bisphosphonate pharmacology and use in the treatment of tumor-induced hypercalcemia and metastatic bone diseases. Drugs 42:919-944
3. Ott SM (1993) Clinical effects of bisphosphonate in involutional osteoporosis. J Bone Miner Res 8:S597-S606
4. Filipino P, Pedetti M, Fedeli L, Cini L, Palumbo R, Boldrini S, Massoui C, Cristallinis S (1995) Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. J Bone Miner Res 10:697-702
5. Reginster JY, Lecart MP, Deroisy R, Sanlet N, Denis D, Ethgen D, Collette J, Franchimont P (1989) Prevention of postmenopausal bone loss by tiludronate. Lancet 79:1469-1471
6. Watt NB, Harris ST, Genant HK, Wasnich R, Miller PD (1990) Intermittent cyclical etidronate treatment in postmenopausal osteoporosis. N Engl J Med 323:73-79
7. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorenson OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271
8. Gianini S, D'Angelo A, Malvasi L, Castrignano R, Pati T, Tronca R, Liberto L, Nobile M, Crepaldi G (1993) Effect of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone 14:137-141
9. Thiebaud D, Burckhard P, Melchior J, Eckert P, Jacquet AF, Schnyder P, Gobelet C (1994) Two years' effectiveness of intravenous pamidronte (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporosis Int 4: 76-83
10. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M, Seeman E, Recker RR, Capizz T, Santora AC II, Lombardi A, Shan RV, Hirsch LJ, Karpf DB (1995) Effect of oral alendronate on bone mineral density and the incidence of fracture in postmenopausal osteoporosis. N Engl J Med 333(22):1437-1443
11. Giannini S, D'Angelo A, Sartori L, Passeri G, Carbonarre LD, Crepaldi G (1996) Continuous and cyclical clodronate therapies and bone density in postmenopausal bone loss. Obstet Gynecol 88:431-436
12. Hanson DA, Weis ME, Bollen A-M, Maslan SL, Singer FR, Eyre D (1992) A specific immunoassay for monitoring human resorption: quantitation of type I collagen cross-lined N-telopeptide in urine. J Bone Miner Res 7:1251-1258
13. Bonde M, Qvist P, Feldelius C, Riis BJ, Christiansen C (1994) Evaluation of an immunoassay for quantitation of type I collagen degradation products in urine. Clin Chem 40:2022-2025
14. Tsai KS, Pan WH, Hsu SHJ, Cheng WC, Chen CK, Chieng PU, Yang RS, Twu ST (1996) Sexual differences in bone markers and bone mineral density of normal Chinese. Calcif Tissue Int 59:454-460
15. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137-1141
16. Eastell R, Cedel SL, Wahner HW, Riggs BL, Melton LJ III (1991) Classification of vertebral fractures. J Bone Miner Res 6:207-215
17. Rizzoli R, Forni M, Schaad MA, Slosman D, Sappino AP, Garcia J, Bonjour JP (1996) Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer. Bone 18:531-537
18. Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, De Deuxchaisnes CN, Geusens P, Hosking D, Jaeger P, Kaufman JM, Leite M, Leon J, Liberman U, Menkes CJ, Meunier JP, Reid I, Rodriguez J, Romanowicz A, Seeman E, Vermeulen A, Hirsh LJ, Lombardi A, Plezia K, Santora AC, Yates AJ, Yuan W (1996) Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 18: 141-150
19. Favus M, Emkey R, Leite M, Devogelaer JP, Rodriguez J, Peverty C, Kaur A, Santora A (1997) Five-year treatment of osteoporosis in postmenopausal women with oral alendronate: effects on bone mass and turnover and safety. J Bone Miner Res 12(suppl 1):189
20. Garnero P, Shin WJ, Gineyts E, Karpf DB, Delmas PD (1994) Comparison of new biochemical markers of bone turnover in later postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700
21. Rosen HN, Dresner-Pollak R, Moses AC, Rosenblatt M, Zeind AJ, Clements JD, Greenspan SL (1994) Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int 54:26-29
22. Garnero P, Gineyts E, Delmas PD (1994) Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 79:780-785
23. TM)-follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 80:864-868
24. Sairanen S, Tahtela R, Laitinen K, Loyttyniemi E, Valimaki MJ (1997) Effects of short-term treatment with clodronate on parameters of bone metabolism and their diurnal variation. Calcif Tissue Int 60:160-163